A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

Genentech, Inc.18 enrolled

Overview

This is a Phase IV, open label, case-controlled, observational study to evaluate the age-adjusted cumulative height velocity in pre-pubertal isolated growth hormone deficient (IGHD) and idiopathic short stature (ISS) participants receiving daily doses of somatropin (recombinant human growth hormone \[rhGH\]; Nutropin) using NuSpin device compared to historical controls from the national cooperative growth study (NCGS).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Growth Hormone Deficiency

Interventions

NuSpinDEVICE

Device for administration of doses of somatropin.

SomatropinDRUG

Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.

Eligibility

Sex: ALLMin age: 2 YearsMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Bone age less than or equal to (\</=) 8 years (females) or \</= 10 years (males) as determined by x-ray of the left hand and wrist obtained within six months before enrollment * Prepubertal males and females by physical exam * Naive to rhGH therapy * Diagnosis of IGHD or ISS by standard pharmacologic testing and no other discernable etiology for short stature * Height standard deviation score (Ht SDS) \</= -1.5 (\</= 5th percentile) for IGHD participants; Ht SDS \</= -2.25 (\</= 1.2 percentile) for ISS participants Exclusion Criteria: * Short stature etiologies other than IGHD or ISS * Participants receiving chronic corticosteroid therapy (greater than \[\>\] 3 months) for other medical conditions * Participants with active malignancy or any other condition that the investigator believes would pose a significant hazard to the participant if rhGH were initiated * Females with turner syndrome * Any previous rhGH treatment * Participation in another simultaneous medical investigation or trial * Pediatric participants with closed epiphyses * Participants prescribed rhGH doses outside the variance of NCGS control participant dosing

Locations (14)

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Scottsdale, Arizona, United States

Unnamed facility

Sacramento, California, United States

Outcomes

Primary Outcomes

Annualized Height Velocity in Response to rhGH Treatment Using the NuSpin Device After Two Years of Treatment

The annualized height velocity (cm per year \[cm/yr\]) over 2 years was calculated as: \[(height in cm at t24 minus (-) height in cm at t0) divided by (date at t24 - date at t0)\] multiplied by 365.25, where, t0 is the baseline measurement visit and t24 is the 2-year measurement visit.

Time frame: Baseline up to Month 24 (Year 2)

Secondary Outcomes

Annualized Height Velocity in Response to rhGH Treatment Using the NuSpin Device for First Year of Treatment

The annualized height velocity (cm/yr) after 1 year was calculated as: \[(height in cm at t12 - height in cm at t0) divided by (date at t12 - date at t0)\] multiplied by 365.25, where, t0 is the baseline measurement visit and t12 is the 1-year measurement visit.

Time frame: Baseline up to Month 12 (Year 1)

Annualized Height Velocity in Response to rhGH Treatment Using the NuSpin Device During the Second Year of Therapy

The annualized height velocity (cm/yr) for second year was calculated as: \[(height in cm at t24 - height in cm at t12) divided by (date at t24 - date at t12)\] multiplied by 365.25, where, t12 is the 1-year measurement visit and t24 is the 2-year measurement visit.

Time frame: Month 12 to Month 24 (Year 1 to Year 2)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.